PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the safety of different doses of BIBR 1048, alone or
in combination with acetylsalicylic acid (ASA), as determined by the rates of bleeding and
other adverse events.
A secondary objective of this trial is to evaluate the anticoagulant effect of different
doses of BIBR 1048, based on the reduction of plasma concentrations of D-dimer, a laboratory
marker for activated coagulation in patients with atrial fibrillation (AF), and to correlate
bleeding and other events with pharmacokinetic (PK) and pharmacodynamic (PD) data.